PARATEK PHARMACEUTICALS INC's ticker is PRTK and the CUSIP is 699374302. A total of 87 filers reported holding PARATEK PHARMACEUTICALS INC in Q3 2016. The put-call ratio across all filers is 0.91 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $267,000 | +11.2% | 49,800 | +6.6% | 0.00% | – |
| Q4 2018 | $240,000 | -47.0% | 46,700 | 0.0% | 0.00% | -100.0% |
| Q3 2018 | $453,000 | -4.8% | 46,700 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $476,000 | -21.6% | 46,700 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $607,000 | -1.8% | 46,700 | +35.4% | 0.00% | 0.0% |
| Q4 2017 | $618,000 | -28.6% | 34,500 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $866,000 | +19.4% | 34,500 | +14.6% | 0.00% | 0.0% |
| Q2 2017 | $725,000 | +44.7% | 30,100 | +15.8% | 0.00% | 0.0% |
| Q1 2017 | $501,000 | +25.2% | 26,000 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $400,000 | +47.1% | 26,000 | +24.4% | 0.00% | – |
| Q3 2016 | $272,000 | -6.5% | 20,900 | 0.0% | 0.00% | – |
| Q2 2016 | $291,000 | +29.9% | 20,900 | +35.7% | 0.00% | – |
| Q1 2016 | $224,000 | -1.8% | 15,400 | +28.3% | 0.00% | -100.0% |
| Q4 2015 | $228,000 | – | 12,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Omega Fund Management, LLC | 2,600,410 | $33,805,000 | 33.22% |
| Abingworth LLP | 1,041,131 | $13,535,000 | 8.41% |
| Roumell Asset Management, LLC | 197,347 | $2,566,000 | 5.65% |
| Trellus Management Company, LLC | 89,700 | $1,166,000 | 2.12% |
| Prosight Management, LP | 148,682 | $1,933,000 | 1.21% |
| Broadfin Capital, LLC | 477,607 | $6,209,000 | 0.97% |
| HIGHLAND CAPITAL MANAGEMENT LP | 959,278 | $12,471,000 | 0.64% |
| ARMISTICE CAPITAL, LLC | 580,000 | $7,540,000 | 0.58% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 103,500 | $1,346,000 | 0.52% |
| Opus Point Partners Management, LLC | 20,000 | $260,000 | 0.51% |